Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Identification of Novel Variants Associated with Fetal Hemoglobin Levels in Healthy Donors (the INTERVAL study)

Emily Kawabata, Samuel Lessard, PhD, Dirk Paul, Paola G Bronson, Robert Peters, Sriram Krishnamoorthy, PhD, William Astle, Adam Butterworth

Blood (2019) 134 (Supplement_1): 2243.

https://doi.org/10.1182/blood-2019-123977

Published: 2019

Journal Articles

Glutathione Ameliorates Bortezomib (Velcade) -Induced Neuronal Toxicity in N2a and SHSY5Y Cells

Jinny Park, MDPhD, Lalita Subedi, MS, Su Jung Park, MD, Oh kyung Lim, ChanJong Yoo, MD PhD, Jong-Suk Kim, MD PhD, Sun Yeou Kim, PhD

Blood (2018) 132 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2018-99-115711

Published: 2018

Journal Articles

Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment

Andrea Bacigalupo, MD, H. Joachim Deeg, MD, Dolores Caballero, MD PhD, Francesca Gualandi, MD, Anna Maria Raiola, MD, Riccardo Varaldo, MD, Carmen Di Grazia, MD, Lucia López Corral, PhD MD, Maria Teresa van Lint, MD

Blood (2016) 128 (22): 671.

https://doi.org/10.1182/blood.V128.22.671.671

Published: 2016

Journal Articles

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada

Hatem Alahwal, MPH, MBBS, Kevin W. Song, MD, Peter Duggan, MD, Heather J. Sutherland, MD PhD, Paola Neri, MD PhD, Raewyn Broady, MBChB, Nizar J. Bahlis, MD, Victor Jimenez-Zepeda, MD

Blood (2016) 128 (22): 2131.

https://doi.org/10.1182/blood.V128.22.2131.2131

Published: 2016

Journal Articles

SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Roland B. Walter, MD PhD, Lori Westendorf, John Valliere-Douglass, PhD, Lucy Pan, PhD, Django Sussman, PhD, Martha Anderson, Weiping Zeng, Ivan Stone, Kerry Klussman, Michelle Ulrich, Mechthild Jonas, PhD, Peter Senter, PhD, Jonathan G. Drachman, MD, Dennis Benjamin, PhD

Blood (2015) 126 (23): 330.

https://doi.org/10.1182/blood.V126.23.330.330

Published: 2015

Journal Articles

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Christine O'Day, PhD, Steve Alley, PhD, Martha Anderson, Kim Emmerton, Weipeng Zeng, Megan M. O'Meara, MD, Eric J. Feldman, MD, Dana A. Kennedy, Maureen C. Ryan, PhD, Dennis Benjamin, PhD

Blood (2015) 126 (23): 3785.

https://doi.org/10.1182/blood.V126.23.3785.3785

Published: 2015

Journal Articles

SGN-CD33A in Combination with Cytarabine or Hypomethylating Agents Demonstrates Enhanced Anti-Leukemic Activity in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, MD, Martha Anderson, Kim Emmerton, Weiping Zeng, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, BCOP, Maureen C. Ryan, PhD, Dennis R. Benjamin, PhD

Blood (2014) 124 (21): 3739.

https://doi.org/10.1182/blood.V124.21.3739.3739

Published: 2014

Journal Articles

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

May S.K. Sutherland, PhD, Roland B. Walter, MD, PhD, Scott C. Jeffrey, PhD, Patrick J. Burke, PhD, Changpu Yu, MD, Kimberly H. Harrington, BS, Ivan Stone, BS, Maureen C. Ryan, PhD, Django Sussman, PhD, Weiping Zeng, MD, Dennis R. Benjamin, PhD, Irwin D. Bernstein, MD, Peter D. Senter, PhD, Jonathan G. Drachman, MD, Julie A. McEarchern, PhD

Blood (2012) 120 (21): 3589.

https://doi.org/10.1182/blood.V120.21.3589.3589

Published: 2012

Journal Articles

Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL),

Shruti Bhatt, Brittany Ashlock, Yaso Natkunam, MD, PhD, Juan Carlos Ramos, MD, Enrique Mesri, PhD, Izidore S Lossos, MD

Blood (2011) 118 (21): 3728.

https://doi.org/10.1182/blood.V118.21.3728.3728

Published: 2011

Journal Articles

The Role of Amino Acids 700–701 of the Factor Va Heavy Chain During Prothrombin Activation by Factor Xa

Jamila Hirbawi, PhD, Paul Y Kim, PhD, Michael E. Nesheim, PhD, Michael Kalafatis, PhD

Blood (2010) 116 (21): 2203.

https://doi.org/10.1182/blood.V116.21.2203.2203

Published: 2010

Journal Articles

Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib.

Erika Suzuki, Susan Demo, PhD, Shirin Arastu-Kapur, PhD, Christopher J Kirk, Ph.D, Mark K Bennett, PhD

Blood (2009) 114 (22): 2852.

https://doi.org/10.1182/blood.V114.22.2852.2852

Published: 2009

Journal Articles

Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms.

Shirin Arastu-Kapur, PhD, Andrew J. Ball, PhD, Janet L. Anderl, Mark K Bennett, PhD, Christopher J Kirk, Ph.D

Blood (2009) 114 (22): 2859.

https://doi.org/10.1182/blood.V114.22.2859.2859

Published: 2009

Journal Articles

Characterization of Bortezomib (Velcade ™) Resistance in a New Set of Human Cell Lines Obtained by Stepwise Selection.

Jie Cai, Ph.D., Xian Jin Lian, M.Sc., Christopher von Roretz, Chaim Shustik, MD, Imed Gallouzi, Philippe Gros, Ph.D.

Blood (2009) 114 (22): 2741.

https://doi.org/10.1182/blood.V114.22.2741.2741

Published: 2009

Journal Articles

CD26/Dipeptidylpeptidase IV Regulates Potency of Selected Hematopoietic Growth Factors through Truncation, and Recovery In Vivo After Cytotoxic Stress.

Hal E. Broxmeyer, PhD, Jonathan Hoggatt, MS, Scott Cooper, Giao Hangoc, DVM, PhD, Louis M. Pelus, PhD, Timothy B. Campbell

Blood (2009) 114 (22): 3602.

https://doi.org/10.1182/blood.V114.22.3602.3602

Published: 2009

Journal Articles

A Novel Function of CD26-Mediated Costimulation in the Cytotoxic Activity of Human CD8+ T Cells in Xenogeneic Chronic Graft-Versus-Host Disease (cGVHD) and GVL Mice Model.

Ryo Hatano, Kei Ohnuma, Taketo Yamada, Wataru Takasawa, Yuko Endo, Yumiko Matsumura, Osamu Hosono, Nam H. Dang, Chikao Morimoto

Blood (2009) 114 (22): 3548.

https://doi.org/10.1182/blood.V114.22.3548.3548

Published: 2009

Journal Articles

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Tony Muchamuel, Shirin Kapur, PhD, Christopher J Kirk, Ph.D, Jing Jiang, M.D., Susan Lee, Mark K Bennett, PhD, Evan Lewis, Jinfu Yang, Mouhannad Jumaa, Eileen Ring, Pasit Phiasivongsa, Han-Jie Zhou, PhD, Zhengping Wang

Blood (2009) 114 (22): 4910.

https://doi.org/10.1182/blood.V114.22.4910.4910

Published: 2009

Journal Articles

Breaking Immune Tolerance to Granule Proteases with Full-Length Antigen Vaccine in Humanized Transgenic Mice Reveals Alternative Antigen Processing and Immunodominance Heirarchy Applicable to Clinical Immunotherapy.

J. Diamond Don, Ph.D, Wendi Zhou, Ph.D, Tumul Srivastava, Ph.D, Ravindra Rawal, Ph.D, Katharine Hagan, Helen A Andersson, Ph.D, J. N. Cooper Laurence, M.D., Jeffrey J. Molldrem, M.D., Simon F. Lacey, PhD, BSc

Blood (2009) 114 (22): 2054.

https://doi.org/10.1182/blood.V114.22.2054.2054

Published: 2009

Journal Articles

Disruption of CXCR4 Utilizing AMD3100 Bypasses Mobilization Deficiency Exhibited by CD26 −/− Mice and Results in Efficient Mobilization of Myeloid Progenitors

Laura A. Paganessi, Andrew L. Walker, Stephanie A. Gregory, MD, Henry C. Fung, MD, Kent W. Christopherson, II, PhD

Blood (2008) 112 (11): 3492.

https://doi.org/10.1182/blood.V112.11.3492.3492

Published: 2008

Journal Articles

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Tony Muchamuel, Monette Aujay, Mark K Bennett, PhD, Maya Dajee, Susan Demo, PhD, Christopher J Kirk, Ph.D, Ying Fang, Jing Jiang, M.D., Evan Lewis, Yan Lu, Guy Laidig, Francesco Parlati, PhD, Jamie Shields, Congcong m Sun, Jinfu Yang, Han-Jie Zhou, PhD

Blood (2008) 112 (11): 3671.

https://doi.org/10.1182/blood.V112.11.3671.3671

Published: 2008

Journal Articles

Dipeptidyl Peptidase Inhibition Accelerates Dendritic Cell Cross Priming of Tumor-Reactive T Cells Resulting in Regression of Established Tumors

Meghaan Walsh, Aviva C Krauss, MD, Jessica PE Davis, Su Young Kim, Martin Guimond, PhD, Crystal L. Mackall, M.D., Terry J Fry, M.D.

Blood (2008) 112 (11): 2579.

https://doi.org/10.1182/blood.V112.11.2579.2579

Published: 2008

NARROW

Identification of Novel Variants Associated with Fetal Hemoglobin Levels in Healthy Donors (the INTERVAL study)

Glutathione Ameliorates Bortezomib (Velcade) -Induced Neuronal Toxicity in N2a and SHSY5Y Cells

Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada

SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

SGN-CD33A in Combination with Cytarabine or Hypomethylating Agents Demonstrates Enhanced Anti-Leukemic Activity in Preclinical Models of AML

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL),

The Role of Amino Acids 700–701 of the Factor Va Heavy Chain During Prothrombin Activation by Factor Xa

Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib.

Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms.

Characterization of Bortezomib (Velcade ™) Resistance in a New Set of Human Cell Lines Obtained by Stepwise Selection.

CD26/Dipeptidylpeptidase IV Regulates Potency of Selected Hematopoietic Growth Factors through Truncation, and Recovery In Vivo After Cytotoxic Stress.

A Novel Function of CD26-Mediated Costimulation in the Cytotoxic Activity of Human CD8+ T Cells in Xenogeneic Chronic Graft-Versus-Host Disease (cGVHD) and GVL Mice Model.

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Breaking Immune Tolerance to Granule Proteases with Full-Length Antigen Vaccine in Humanized Transgenic Mice Reveals Alternative Antigen Processing and Immunodominance Heirarchy Applicable to Clinical Immunotherapy.

Disruption of CXCR4 Utilizing AMD3100 Bypasses Mobilization Deficiency Exhibited by CD26 −/− Mice and Results in Efficient Mobilization of Myeloid Progenitors

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Dipeptidyl Peptidase Inhibition Accelerates Dendritic Cell Cross Priming of Tumor-Reactive T Cells Resulting in Regression of Established Tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only